Activity Description & Educational Objectives
In this activity, an expert in oncology provides an overview of the current challenges in the management of gastroesophageal region cancers, the evolving pharmacologic treatment landscape, and the latest evidence on the benefits, limitations, and roles of targeted agents in patients with advanced gastric cancer.
Upon completion of this activity, participants should be better able to:
- Describe the relevant molecular targets in gastric cancer and characteristics of the currently available of investigational agents directed against these targets
- Demonstrate knowledge of the heterogeneity of the esophagogastric cancers (subtypes with differences in etiology, location, histology, and biology) and associated implications for prognosis and determination of an optimal treatment approach
- Discuss the efficacy/safety profiles and potential clinical roles of the latest targeted treatment approaches for gastric cancers
- Develop and implement individualized, evidence-based treatment plans for patients with gastric cancers that are based on thorough assessment of tumor and patient characteristics, risks and benefits of available therapies, and latest guidelines/consensus recommendations
This activity has been designed to meet the educational needs of medical oncologists and other clinicians involved in treating gastric cancer.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: October 10, 2013 - October 09, 2014
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Axel Grothey, MD
Professor of Oncology
Axel Grothey, MD, has no financial interests/relationships or affiliations in relation to this activity.
Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education
Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5457-14-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.